BioMed Stocks On the Move: GeoVax Labs, Nova Mentis, SIGA and PharmaDrug; Life Sciences Leaders Report Latest Advances in Antiviral Vaccines, and Novel Therapeutics for Oncology, Glaucoma and Autism
Retrieved on:
Monday, May 23, 2022
Psilocybin, PDUFA, Public health, EST, PEP, Method, Contract, Government, Substituted tryptamine, Monkeypox, United States Department of Defense, Interview, Autism, Esophageal cancer, Prostate cancer, SUPER, NDA, Health Canada, SIGA Technologies, SEC, Cancer, MMWR, Fragile X syndrome, News, Clinical trial, COVID-19, Patent, ASD, Pharmaceutics, CSE, Smallpox, CMO, CDC, Malaria, GLOBE, FXS, NOVA, GeoVax, Infection, Goal, Vaccine, Plasma protein binding, IV, Defense, Trial of the century, FDA, Autism spectrum, Biotechnology, Toxicity, DMT, Therapy, MVA, Toronto Institute of Pharmaceutical Technology, Wall Street, Cepharanthine, History, NASDAQ, OTC, NEXT, Intraocular pressure, Industry, Antigen, Glaucoma, BARDA, CEO, Pharmaceutical industry, Animal, Pension fund, MD
As the global pharma market suprasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential growth opportunities.
Key Points:
- As the global pharma market suprasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential growth opportunities.
- As the biotech sector rebounds from cyclical lows, institutional investors are increasingly eyeing early-stage biotech stocks for upside potential delivering alpha.
- However, developing vaccines against global public health threats such as malaria, is also part of our longer-term focus.
- Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.